Real-world study finds no excess amputations with flozins
The observational research compared three drugs in the class with gliptin agents
Patients with type 2 diabetes initiated on an SGLT2 inhibitor are at no more risk of an amputation below the knee than those taking a DPP-4 inhibitor, at least in the first year, a real-world study suggests.
In the largest observational study on the topic to date, researchers compared records from 208,000 patients with type 2 diabetes in Canadian and UK databases who were prescribed an SGLT2 inhibitor with the same number of matched patients on a DPP-4 inhibitor.
Over a mean exposure to the drugs of 11 months, the amputation